Development of Safe Drugs: The hERG Challenge
暂无分享,去创建一个
[1] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[2] M. Mezei,et al. Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.
[3] Clayton Springer,et al. A fingerprint pair analysis of hERG inhibition data , 2013, Chemistry Central Journal.
[4] D. Brown,et al. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis. , 2012, Bioorganic & medicinal chemistry letters.
[5] A. Cavalli,et al. Computational design and discovery of "minimally structured" hERG blockers. , 2012, Journal of medicinal chemistry.
[6] Ruifeng Liu,et al. General Purpose 2D and 3D Similarity Approach to Identify hERG Blockers , 2016, J. Chem. Inf. Model..
[7] N. Thornberry,et al. Potent and selective proline derived dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[8] C. Leem,et al. A novel hypothesis for the binding mode of HERG channel blockers. , 2006, Biochemical and biophysical research communications.
[9] M. Sanguinetti,et al. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[10] Bahareh Tabatabaee Amid,et al. Effect of different drying techniques on flowability characteristics and chemical properties of natural carbohydrate-protein Gum from durian fruit seed , 2013, Chemistry Central Journal.
[11] W. Catterall,et al. Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs , 2016, Nature.
[12] An NMR study of the N‐terminal domain of wild‐type hERG and a T65P trafficking deficient hERG mutant , 2011, Proteins.
[13] G. Gintant,et al. Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers. , 2012, Life sciences.
[14] Gert Vriend,et al. Toward a Consensus Model of the hERG Potassium Channel , 2010, ChemMedChem.
[15] P. Kuchel,et al. The N–Terminal Tail of hERG Contains an Amphipathic α–Helix That Regulates Channel Deactivation , 2011, PloS one.
[16] D. Escande,et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. , 2001, The Journal of pharmacology and experimental therapeutics.
[17] H. Strauss,et al. Inactivation of voltage-gated cardiac K+ channels. , 1998, Circulation research.
[18] Istvan J Enyedy,et al. In silico prediction of hERG inhibition. , 2015, Future medicinal chemistry.
[19] Xianhai Huang,et al. Case Studies in Modern Drug Discovery and Development: Huang/Case Studies Drug Discovery , 2012 .
[20] P. Fernandes,et al. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools , 2014, Journal of enzyme inhibition and medicinal chemistry.
[21] R. Friesner,et al. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.
[22] Gabriele Cruciani,et al. Predictive models for hERG potassium channel blockers. , 2005, Bioorganic & medicinal chemistry letters.
[23] M. Sutcliffe,et al. Activation Gating of hERG Potassium Channels , 2007, Journal of Biological Chemistry.
[24] Robert Preissner,et al. WITHDRAWN—a resource for withdrawn and discontinued drugs , 2015, Nucleic Acids Res..
[25] Roy J. Vaz,et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.
[26] Sichao Wang,et al. Recent developments in computational prediction of HERG blockage. , 2013, Current topics in medicinal chemistry.
[27] Tingjun Hou,et al. ADME evaluation in drug discovery , 2002, Journal of molecular modeling.
[28] Bruno O Villoutreix,et al. Computational investigations of hERG channel blockers: New insights and current predictive models. , 2015, Advanced drug delivery reviews.
[29] Serdar Durdagi,et al. Combined Receptor and Ligand-Based Approach to the Universal Pharmacophore Model Development for Studies of Drug Blockade to the hERG1 Pore Domain , 2011, J. Chem. Inf. Model..
[30] F. Manning,et al. Review of the Fialuridine (FIAU) Clinical Trials , 1995 .
[31] F. Spertini,et al. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. , 1999, The Journal of allergy and clinical immunology.
[32] Yumi N Imai,et al. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach. , 2009, Journal of medicinal chemistry.
[33] T. Giles,et al. Death associated with ventricular arrhythmia and thioridazine hydrochloride. , 1968, JAMA.
[34] Hui-zhen Wang,et al. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels. , 2004, Acta pharmacologica Sinica.
[35] D. Snyders,et al. High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.
[36] Katsumi Yoshida,et al. Quantitative Structure-Activity Relationship Studies on Inhibition of HERG Potassium Channels , 2006, J. Chem. Inf. Model..
[37] M. Sanguinetti,et al. SYMPOSIUM REVIEW: Revealing the structural basis of action of hERG potassium channel activators and blockers , 2010, The Journal of physiology.
[38] Antranig Basman,et al. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. , 2004, Progress in biophysics and molecular biology.
[39] Charlotte K. Colenso,et al. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking , 2016, Biochemical pharmacology.
[40] A. Arnold,et al. An NMR investigation of the structure, function and role of the hERG channel selectivity filter in the long QT syndrome. , 2013, Biochimica et biophysica acta.
[41] J. Nerbonne,et al. Molecular physiology of cardiac repolarization. , 2005, Physiological reviews.
[42] M. Bunnage. Getting pharmaceutical R&D back on target. , 2011, Nature chemical biology.
[43] S. Gayen,et al. Structural insight into the transmembrane segments 3 and 4 of the hERG potassium channel , 2014, Journal of peptide science : an official publication of the European Peptide Society.
[44] S. Edmondson. Discovery of Potent and Selective Orally Bioavailable β-Substituted Phenylalanine Derived Dipeptidyl Peptidase IV Inhibitors. , 2005 .
[45] Visakan Kadirkamanathan,et al. Lead Optimization Using Matched Molecular Pairs: Inclusion of Contextual Information for Enhanced Prediction of hERG Inhibition, Solubility, and Lipophilicity , 2010, J. Chem. Inf. Model..
[46] J. Warmke,et al. A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[47] Michael J Sutcliffe,et al. Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs , 2006, Molecular Pharmacology.
[48] J. Li,et al. A two-state homology model of the hERG K+ channel: application to ligand binding. , 2005, Bioorganic & medicinal chemistry letters.
[49] Lu Chen,et al. A Critical Assessment of Combined Ligand- and Structure-Based Approaches to hERG Channel Blocker Modeling , 2011, J. Chem. Inf. Model..
[50] Z. Wang,et al. Inactivation block of the HERG human cardiac K+ channels by RP58866 , 1999, British journal of pharmacology.
[51] B. Charles,et al. Evaluation Of Drug Candidates For Preclinical Development: Pharmacokinetics, Metabolism, Pharmaceutics, And Toxicology , 2010 .
[52] A. Cavalli,et al. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.
[53] Gregory W. Kauffman,et al. Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.
[54] Min Li,et al. High throughput screening technologies for ion channels , 2015, Acta Pharmacologica Sinica.
[55] M. Cadene,et al. X-ray structure of a voltage-dependent K+ channel , 2003, Nature.
[56] Adriaan P IJzerman,et al. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide. , 2013, Journal of medicinal chemistry.
[57] G. Robertson,et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.
[58] Mark E. Anderson,et al. Cardiac ion channels. , 2002, Annual review of physiology.
[59] K. Servick. A painstaking overhaul for cardiac safety testing. , 2016, Science.
[60] Daniela Schuster,et al. Experimentally Validated hERG Pharmacophore Models as Cardiotoxicity Prediction Tools , 2014, J. Chem. Inf. Model..
[61] Beiyan Zou,et al. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay , 2016, Acta Pharmacologica Sinica.
[62] A. Brown,et al. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. , 1993, Molecular pharmacology.
[63] R. M. Owen,et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.
[64] Kaichiro Kamiya,et al. Molecular Determinants of hERG Channel Block , 2006, Molecular Pharmacology.
[65] Desmond O'Connor,et al. 4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia. , 2005, Bioorganic & medicinal chemistry letters.
[66] S. Oiki,et al. Topological Mapping of the Asymmetric Drug Binding to the Human Ether-à-go-go-Related Gene Product (HERG) Potassium Channel by Use of Tandem Dimers , 2008, Molecular Pharmacology.
[67] J. Morais-Cabral,et al. Structural Properties of PAS Domains from the KCNH Potassium Channels , 2013, PloS one.
[68] D J Triggle,et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.
[69] Z. Rankovic,et al. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.
[70] Alex M Aronov,et al. Predictive in silico modeling for hERG channel blockers. , 2005, Drug discovery today.
[71] Li Zhiyuan,et al. A Comparison of the Performance and Application Differences Between Manual and Automated Patch-Clamp Techniques , 2012, Current chemical genomics.
[72] S. Adhikari,et al. Optimization of tetrahydronaphthalene inhibitors of Raf with selectivity over hERG. , 2016, Bioorganic & medicinal chemistry letters.
[73] Gea-Ny Tseng,et al. Gating Charges in the Activation and Inactivation Processes of the hERG Channel , 2004, The Journal of general physiology.
[74] Matthew Clark,et al. Development and Evaluation of an in Silico Model for hERG Binding , 2006, J. Chem. Inf. Model..
[75] Michael C Sanguinetti,et al. Structural Determinants of HERG Channel Block by Clofilium and Ibutilide , 2004, Molecular Pharmacology.
[76] J. Kiehn,et al. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. , 2006, Current pharmaceutical design.
[77] Michael C Sanguinetti,et al. Molecular Determinants of Voltage-dependent Human Ether-a-Go-Go Related Gene (HERG) K+ Channel Block* , 2002, The Journal of Biological Chemistry.
[78] Roderick MacKinnon,et al. Structure of the voltage-gated K+ channel Eag1 reveals an alternative voltage sensing mechanism , 2016, Science.
[79] M. Waring,et al. A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.
[80] M. Jiang,et al. Negative Charges in the Transmembrane Domains of the HERG K Channel Are Involved in the Activation- and Deactivation-gating Processes , 2003, The Journal of general physiology.
[81] G. Keller,et al. Mechanisms of drug induced QT interval prolongation. , 2010, Current drug safety.
[82] J. Hancox,et al. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm‐1 scorpion toxin , 2003, FEBS letters.
[83] M. Raida,et al. NMR solution structure of the N-terminal domain of hERG and its interaction with the S4-S5 linker. , 2010, Biochemical and biophysical research communications.
[84] P. Bennett,et al. Saxitoxin Is a Gating Modifier of hERG K+ Channels , 2003, The Journal of general physiology.
[85] A. Stary-Weinzinger,et al. New potential binding determinant for hERG channel inhibitors , 2016, Scientific Reports.
[86] Ting-Feng Lin,et al. The Subfamily-specific Assembly of Eag and Erg K+ Channels Is Determined by Both the Amino and the Carboxyl Recognition Domains* , 2014, The Journal of Biological Chemistry.
[87] M T D Cronin,et al. Prediction of hERG K+ blocking potency: Application of structural knowledge , 2004, SAR and QSAR in environmental research.
[88] Andreas Bender,et al. Prospective Validation of a Comprehensive In silico hERG Model and its Applications to Commercial Compound and Drug Databases , 2010, ChemMedChem.
[89] E. Campbell,et al. Crystal Structure of a Mammalian Voltage-Dependent Shaker Family K+ Channel , 2005, Science.
[90] Gary Yellen,et al. The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.
[91] G. Keserü. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.
[92] Serdar Durdagi,et al. Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding , 2012, J. Chem. Inf. Model..
[93] U. Zachariae,et al. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. , 2009, Journal of medicinal chemistry.
[94] Jules C. Hancox,et al. Assessing hERG Pore Models As Templates for Drug Docking Using Published Experimental Constraints: The Inactivated State in the Context of Drug Block , 2014, J. Chem. Inf. Model..
[95] Youyong Li,et al. ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. , 2012, Molecular pharmaceutics.
[96] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[97] Y Rudy,et al. Cellular consequences of HERG mutations in the long QT syndrome: precursors to sudden cardiac death. , 2001, Cardiovascular research.
[98] J. Nix,et al. Individual Ion Binding Sites in the K(+) Channel Play Distinct Roles in C-type Inactivation and in Recovery from Inactivation. , 2016, Structure.
[99] A. Aronov. Ligand structural aspects of hERG channel blockade. , 2008, Current topics in medicinal chemistry.
[100] M. Sanguinetti,et al. Single HERG delayed rectifier K+ channels expressed in Xenopus oocytes. , 1997, The American journal of physiology.
[101] Michael C Sanguinetti,et al. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. , 2003, Molecular pharmacology.
[102] G. Robertson,et al. Fluorescence-Tracking of Activation Gating in Human ERG Channels Reveals Rapid S4 Movement and Slow Pore Opening , 2010, PloS one.
[103] Alexander Tropsha,et al. Tuning HERG out: antitarget QSAR models for drug development. , 2014, Current topics in medicinal chemistry.
[104] M. Sanguinetti,et al. Delayed rectifier outward K+ current is composed of two currents in guinea pig atrial cells. , 1991, The American journal of physiology.
[105] Qingxin Li,et al. Structure of the Cyclic Nucleotide-Binding Homology Domain of the hERG Channel and Its Insight into Type 2 Long QT Syndrome , 2016, Scientific Reports.
[106] D. Fedida,et al. Sequence of gating charge movement and pore gating in HERG activation and deactivation pathways. , 2015, Biophysical journal.
[107] M. Sanguinetti,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[108] S. De Lombaert,et al. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists. , 2004, Journal of medicinal chemistry.
[109] C. Stevens,et al. Crystal structure of the tetramerization domain of the Shaker potassium channel , 1998, Nature.
[110] Jeffrey M Schussler,et al. Drug-induced QT interval prolongation: mechanisms and clinical management , 2012, Therapeutic advances in drug safety.
[111] T. Claydon,et al. Voltage-Dependent Gating of hERG Potassium Channels , 2012, Front. Pharmacol..
[112] O. Kudlacek,et al. Mechanism of hERG Channel Block by the Psychoactive Indole Alkaloid Ibogaine , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[113] F. Österberg,et al. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods , 2005, FEBS letters.
[114] Yi-Ping Phoebe Chen,et al. Structure-based drug design to augment hit discovery. , 2011, Drug discovery today.
[116] T. Colatsky,et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress. , 2016, Journal of pharmacological and toxicological methods.
[117] A. Brown,et al. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. , 1996, Circulation.
[118] M K Pugsley,et al. Principles of Safety Pharmacology , 2008, Handbook of Experimental Pharmacology.
[119] Cavero,et al. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.
[120] A. Aronov. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. , 2006, Journal of medicinal chemistry.
[121] H. Strauss,et al. Modulation of HERG affinity for E‐4031 by [K+]o and C‐type inactivation , 1997, FEBS letters.
[122] Michael Houghton,et al. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. , 2014, Toxicology letters.
[123] Satya P. Gupta,et al. Ion channels and their inhibitors , 2011 .
[124] U. Nielsch,et al. New Approaches to Drug Discovery , 2016, Handbook of Experimental Pharmacology.
[125] K. Tsao,et al. 4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists II. , 2002, Bioorganic & medicinal chemistry letters.
[126] D. Fedida,et al. Gating charge movement precedes ionic current activation in hERG channels , 2013, Channels.
[127] Bernd Beck,et al. A Composite Model for hERG Blockade , 2008, ChemMedChem.
[128] Zhiyi Yu,et al. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs. , 2014, Toxicology and applied pharmacology.
[129] A. Camm,et al. Drug induced QT prolongation and torsades de pointes , 2003, Heart.
[130] Jules C Hancox,et al. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. , 2004, Biochemical and biophysical research communications.
[131] J. Kosek,et al. SUDDEN DEATH DURING TREATMENT WITH PHENOTHIAZINE DERIVATIVES. , 1965, JAMA.
[132] A. Ganesan,et al. Target fishing: a key to unlock the One-To-Many puzzle in drug discovery , 2016 .
[133] Paul Czodrowski,et al. hERG Me Out , 2013, J. Chem. Inf. Model..
[134] Kristeen A Pareja,et al. Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs , 2013, Channels.
[135] Jamie I Vandenberg,et al. Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-à-go-go-Related Gene Channels , 2008, Molecular Pharmacology.
[136] John S. Mitcheson,et al. Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.
[137] Sean Ekins,et al. Challenges Predicting Ligand-Receptor Interactions of Promiscuous Proteins: The Nuclear Receptor PXR , 2009, PLoS Comput. Biol..
[138] E. Green,et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.
[139] Andrea Cavalli,et al. An Automated Docking Protocol for hERG Channel Blockers , 2013, J. Chem. Inf. Model..
[140] G Duker,et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? , 1997, The Journal of pharmacology and experimental therapeutics.
[141] S Durdagi,et al. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs. , 2010, Current medicinal chemistry.
[142] J. Brugada,et al. Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.
[143] W. Crumb,et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.
[144] Stefan A. Mann,et al. hERG K(+) channels: structure, function, and clinical significance. , 2012, Physiological reviews.
[145] J. Valentin,et al. An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.
[146] E. Campbell,et al. Voltage Sensor of Kv1.2: Structural Basis of Electromechanical Coupling , 2005, Science.
[147] J. Lampe. Case Studies in Modern Drug Discovery and Development , 2013 .
[148] J. Hancox,et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.
[149] P. Focia,et al. Structural basis of TEA blockade in a model potassium channel , 2005, Nature Structural &Molecular Biology.
[150] R. MacKinnon,et al. Chemistry of ion coordination and hydration revealed by a K+ channel–Fab complex at 2.0 Å resolution , 2001, Nature.
[151] The S4–S5 Linker Acts as a Signal Integrator for hERG K+ Channel Activation and Deactivation Gating , 2012, PloS one.
[152] E. Grishin,et al. Dynamic conformational changes of extracellular S5–P linkers in the hERG channel , 2005, The Journal of physiology.
[153] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[154] J. Balser,et al. Probing the Interaction Between Inactivation Gating and d-Sotalol Block of HERG , 2000, Circulation research.
[155] You-Jung Park,et al. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[156] S. Thomson,et al. Mechanistic Insight into Human ether-à-go-go-related Gene (hERG) K+ Channel Deactivation Gating from the Solution Structure of the EAG Domain , 2010, The Journal of Biological Chemistry.
[157] M. Zacharias,et al. Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents. , 2004, Molecular pharmacology.
[158] Bennie Zak,et al. Progress in Medicinal Chemistry , 1964 .
[159] M. Sutcliffe,et al. Drug block of the hERG potassium channel: Insight from modeling , 2007, Proteins.
[160] M. Sanguinetti,et al. hERG potassium channels and cardiac arrhythmia , 2006, Nature.